Anti-VEGF agents have shown synergy with ICIs in select solid malignancies, resulting in FDA approval of these combinations in hepatocellular carcinoma and renal cell carcinoma (101). The gene discussed is VEGFA; the disease is hereditary clear cell renal cell carcinoma.